In fact, only one brand held steady from the April rankings: AbbVie’s Skyrizi maintained its top spot, thanks to a May spending total that weighed in only $500,000 lower than April’s.

Meanwhile, AbbVie’s Skyrizi was pushed down to second place after taking home the top spot in April. The psoriasis treatment spent an estimated $34.2 million on TV advertising — the most of any brand ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

If you buy something via one of our links, we may earn a commission. The Enyopro 75-Gallon Outdoor Storage Box is exactly what you need to keep your patio, deck, backyard, or garage free of clutter.

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Natural gas back at mid-$3 on modest storage build, impending data blackout By Investing.com - Oct 26, 2023 9 Investing.com - US natural gas futures jumped 3% on Thursday, returning to the mid-$3 ...

Compared with the general population, patients with ulcerative colitis (UC) had an additional risk of developing cancer, with about two to three more cases per 1000 person-years, regardless of ...

A fatal multivehicle crash on I-75 in Marietta blocked traffic for about two hours late Tuesday morning. The deadly crash happened at around 10:30 a.m. in the northbound lanes of the interstate at ...

Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV season.

Key drugs Skyrizi and Rinvoq are expected to grow by more than $6 billion in 2025. The company also announced the licensing of amylin analog GUBamy from Gubra. This represents AbbVie’s first ...